The Clinical Resource You and Your Patients Need
Endocrine-disrupting chemicals are linked to a growing burden of hormonal, metabolic, and reproductive disorders. The primary research is extensive. The clinical guidance is still remarkably sparse.
The Clinical Portal gives you the evidence-based education, clinical assessment tools, and ready-to-use patient materials to address EDC exposure in your practice — concisely, confidently, and without adding hours to your workload.
This portal is designed for qualified healthcare professionals. All content is evidence-based and referenced. It is intended to support — not replace — clinical judgement. Nothing on this page constitutes medical advice.
What the evidence says — and what most clinicians were never taught
The science on endocrine-disrupting chemicals is not new, and it is not fringe. Over the past three decades, a substantial body of peer-reviewed research has established that endocrine-disrupting chemicals — synthetic compounds capable of interfering with the body's hormonal systems — are ubiquitous in the modern environment and measurably linked to a wide range of clinical outcomes. The problem is not a lack of evidence. The problem is a lack of translation into everyday care.
Formal Positions
- The Endocrine Society has published two landmark Scientific Statements on endocrine-disrupting chemicals and has repeatedly made clear that the evidence base is sufficient to warrant concern, especially across reproductive, metabolic, thyroid, and developmental outcomes.
- WHO / UNEP formally identified endocrine disruptors as a global threat and called for stronger public-health and regulatory responses.
- NIEHS continues to treat endocrine disruption as a priority research area, with relevance across reproductive, developmental, metabolic, and neurological endpoints.
- European regulatory frameworks now reflect the weight of the evidence through formal criteria and restrictions relevant to endocrine-active chemicals.
The Practical Clinical Problem
- EDC exposure is not a standard component of most medical or allied-health curricula.
- There are no widely adopted mainstream guidelines for assessing or counselling patients on endocrine-disruptor exposure in routine practice.
- Frontline clinicians often recognise the relevance of the issue conceptually, but lack concise tools, structured language, and consultation-ready materials.
- Validated assessment tools exist, but they remain underused and largely unknown in many English-speaking clinical environments.
For clinicians who want the broader systems-level framing before going deeper into chemical families or patient tools, the portal includes a dedicated primer on why EDCs should be understood as a public-health problem — not merely a niche toxicology topic, but a population-scale clinical and policy issue shaped by mixtures, low-dose biology, critical windows, and regulatory lag.
Read the Public Health PrimerEconomic Burden
A 2016 analysis published in The Lancet Diabetes & Endocrinology estimated that endocrine-disruptor-attributable disease costs the European Union approximately €163 billion per year — equivalent to 1.28% of EU GDP. The authors noted that this figure is likely a significant underestimate.
EDCs as a Public Health Problem
Clinical primer on population-level exposure, trend data, economic burden, and clinical relevance.
Read the PrimerHow Exposure Happens
Exposure is not only about what is in a product. It is also about how chemicals reach the body and how long they linger there.
Ingestion
Food, water, packaging, can linings, storage containers, cookware
Eating and drinking create repeated daily contact with relevant materials and residues.
Inhalation
Indoor air, vapors, dust, fragranced products, sprays
Breathing adds ongoing low-dose exposure opportunities inside the home.
Dermal / Mucosal
Personal care, lotions, feminine care, intimate products
Some tissues allow faster or more direct absorption than people often assume.
Dust / Hand-to-Mouth
Furniture dust, floors, electronics, children's items
Especially relevant in household environments and for children's day-to-day contact patterns.
A clinically relevant lens: EDCs, feminine health, and fertility
For many clinicians, one of the clearest and most immediately relevant entry points into endocrine-disruption science is feminine health. The literature does not reduce this issue to a single diagnosis or a single chemical family. Instead, it points to a broad pattern: hormone-active environmental exposures are biologically plausible contributors across multiple estrogen-sensitive, reproductive, and fertility-related endpoints.
Endometriosis and adenomyosis contexts where cumulative hormone disruption and inflammation may be relevant.
Fibroids and other estrogen-responsive tissue outcomes.
PCOS and ovulatory-function questions that intersect with metabolic and endocrine signalling.
Reduced fertility, ovarian reserve concerns, and time-to-pregnancy questions where exposure reduction may be a prudent adjunct.
Pregnancy and preconception windows where low-dose and cumulative exposure deserve especially careful clinical communication.
The goal of this section is not to overstate certainty or suggest a one-cause model of women’s health. The goal is to equip clinicians with a concise, evidence-aware framework for when EDC exposure belongs in the conversation — especially in practices focused on reproductive-age women, fertility, prenatal care, and hormone-sensitive conditions.
The linked subpage is designed as a free clinical primer. It gives enough depth to be genuinely useful while clearly bridging into the fuller paid feminine-health and fertility document inside the Clinical Support Package.
Explore EDCs & Feminine HealthBuilt for clinicians who see the gap
If your patients are asking about hormones, fertility, thyroid health, metabolic function, pregnancy, chronic disease, or everyday environmental exposures, this portal gives you a structured way to respond — without having to build that framework yourself.
GPs & Family Medicine Physicians
First point of contact for patients with hormonal, metabolic, and reproductive concerns. Ideal for initial screening and brief counselling.
Endocrinologists
Managing the disorders most directly linked to endocrine-disruptor exposure. The evidence base in this portal is directly relevant to your patient population.
OBGYNs & Midwives
Prenatal and reproductive-age exposure windows are among the highest-sensitivity periods. The portal is especially useful for this clinical context.
Dietitians & Nutritionists
Dietary exposure is a primary route for many chemical families, and medical nutrition support is a core pillar of the framework.
Paediatricians
Children represent a uniquely vulnerable population. Caregiver counselling tools and priority patient profiles are especially relevant here.
Naturopathic / Integrative Medicine
Your patients are often already asking these questions. The portal provides a more rigorous evidence structure and clinical language.
Occupational Health Physicians
Occupational exposure remains under-addressed. Priority patient profiles include occupationally exposed groups.
Oncology & Cancer Care Teams
Hormone-sensitive cancers and endocrine-disruptor exposure share a growing evidence base. Ongoing exposure reduction can be a relevant counselling adjunct.
From evidence to practice — in three steps
The Clinical Portal is structured around the three things a clinician actually needs: to understand the problem deeply, to assess which patients are most affected, and to communicate effectively without adding time to an already pressured consultation.
Understand
Build a rigorous, evidence-based clinical understanding of the endocrine-disruptor problem — from mechanisms of action to chemical families, from public-health framing to female health implications. The educational layer is organised for clinical use, not academic wandering.
Assess
Use validated tools to evaluate a patient’s probable exposure burden and identify who needs priority counselling. The EDES-10 (Endocrine Disruptor Exposure Screen) and EDES-W (Women’s Endocrine Disruptor Exposure Screen) questionnaires, scoring guides, and priority patient logic create a more defensible clinical process.
Counsel & Support
Communicate clearly and confidently using ready-made scripts, a patient-facing language guide, and printer-ready handouts. Everything is designed to reduce prep time and increase clinical usability.
Designed for real clinical environments
Concise and consultation-ready
Every document is structured for use in practice, not academic study.
Referenced but not overwhelming
All content is evidence-based and cited, without requiring the user to read the primary literature first.
Patient-ready where it counts
The handouts and script tools are designed to be used directly with patients, without editing.
The Clinical Support Package — full contents
Three modules. One coherent clinical framework. Everything moves from education to assessment to patient support.
Module A
Understand — Clinical Education
Module B
Assess — Clinical Tools
Module C
Educate & Support Patients
Start here — free clinical resource
The EDC Clinical Starter Pack is the correct entry point for clinicians who want to assess the quality of the framework before purchasing the full package. The free resource must feel complete enough to be genuinely useful on its own, while also making the broader portal feel worth entering.
EDC Evidence Matrix
The 4 highest-priority chemical families, with mechanisms, human outcomes, strength of evidence, and fastest practical actions.
Mechanism Overview
A brief, visual introduction to how EDCs interfere with hormonal systems at receptor, cellular, and systemic levels.
First Counselling Script
A concise consultation-ready script for introducing endocrine-disruptor exposure in under two minutes.
EDES Screening Questionnaires & Supporting Material
Introductory versions of the EDES-10 and EDES-W (Women's) Endocrine Disruptor Exposure Screening questionnaires — with basic scoring guidance and a summary of priority patient groups. Enough to trial the screening approach before accessing the full clinical tools.
No fluff. No wellness marketing. Peer-reviewed evidence, structured for clinical use — in a format you can open between patients.
Get the Free Clinical Starter PackWhat the evidence says
The Endocrine Society (2015)
“Accumulating evidence supports the conclusion that endocrine-disrupting chemicals affect male and female reproduction, thyroid function, metabolism and obesity, insulin and glucose homeostasis, and neuroendocrinology.”
WHO / UNEP (2013)
“Endocrine disruptors represent a global threat and the scientific evidence is strong enough to warrant action.”
NIEHS
“Endocrine-disrupting chemicals remain among the Institute’s priority research areas across reproductive, developmental, metabolic, and neurological outcomes.”
Trasande et al., The Lancet (2016)
“EDC-attributable disease costs in the EU estimated at approximately €163 billion annually.”
Vandenberg et al., Endocrine Reviews (2012)
“Landmark work on non-monotonic dose-response relationships, demonstrating biological activity at trace concentrations below conventional assumptions.”
The Clinical Portal draws on a large peer-reviewed body of literature, including primary research, systematic reviews, and formal institutional statements. A full reference list is available within the package.
Get your free Clinical Starter Pack
Enter your details below and we will send the EDC Clinical Starter Pack directly to your inbox. No spam. No sales pressure. Just clinical-grade content, free.
Access the full Clinical Support Package
Everything you need to understand, assess, and counsel patients on endocrine-disruptor exposure — in one evidence-based clinical package.
€77 — One-time purchase. Lifetime access. Free updates for 12 months.
Endocrine Resilience clinical materials are designed to support healthcare professionals in patient education and counselling. They do not constitute medical advice and are not a substitute for clinical training or professional judgement. All content is evidence-based and referenced. © Endocrine Resilience 2025.